MA49886A - Anticorps anti-par2 et leurs utilisations - Google Patents
Anticorps anti-par2 et leurs utilisationsInfo
- Publication number
- MA49886A MA49886A MA049886A MA49886A MA49886A MA 49886 A MA49886 A MA 49886A MA 049886 A MA049886 A MA 049886A MA 49886 A MA49886 A MA 49886A MA 49886 A MA49886 A MA 49886A
- Authority
- MA
- Morocco
- Prior art keywords
- par2 antibodies
- par2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472462P | 2017-03-16 | 2017-03-16 | |
| US201862637766P | 2018-03-02 | 2018-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49886A true MA49886A (fr) | 2020-06-24 |
Family
ID=61827709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049886A MA49886A (fr) | 2017-03-16 | 2018-03-16 | Anticorps anti-par2 et leurs utilisations |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10836822B2 (fr) |
| EP (2) | EP3596125B1 (fr) |
| JP (3) | JP7222901B2 (fr) |
| KR (1) | KR102711884B1 (fr) |
| CN (1) | CN110446720B (fr) |
| AU (3) | AU2018235031B2 (fr) |
| BR (1) | BR112019018752A2 (fr) |
| CA (1) | CA3055251A1 (fr) |
| CL (1) | CL2019002626A1 (fr) |
| CO (1) | CO2019010975A2 (fr) |
| CR (1) | CR20190417A (fr) |
| DK (1) | DK3596125T3 (fr) |
| ES (1) | ES3056721T3 (fr) |
| FI (1) | FI3596125T3 (fr) |
| HR (1) | HRP20251643T1 (fr) |
| IL (1) | IL269134B2 (fr) |
| LT (1) | LT3596125T (fr) |
| MA (1) | MA49886A (fr) |
| MX (1) | MX2019010802A (fr) |
| NZ (1) | NZ757915A (fr) |
| PH (1) | PH12019502087A1 (fr) |
| PL (1) | PL3596125T3 (fr) |
| PT (1) | PT3596125T (fr) |
| RS (1) | RS67581B1 (fr) |
| SG (1) | SG11201908056QA (fr) |
| SI (1) | SI3596125T1 (fr) |
| TW (1) | TWI788332B (fr) |
| UA (1) | UA125757C2 (fr) |
| WO (1) | WO2018167322A1 (fr) |
| ZA (1) | ZA201906004B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2647706B1 (fr) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| WO2017110981A1 (fr) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-myostatine et procédés d'utilisation |
| EP3494991A4 (fr) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Composition pour la prophylaxie ou le traitement de maladies liées à il-8 |
| WO2018139623A1 (fr) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-sclérostine et procédés d'utilisation |
| MX2019010802A (es) * | 2017-03-16 | 2019-10-30 | Medimmune Ltd | Anticuerpos anti-par2 y usos de los mismos. |
| US12214216B1 (en) | 2019-10-16 | 2025-02-04 | Helen Feng | Photon enhanced bone growth system and method |
| SMT202500106T1 (it) | 2020-08-18 | 2025-05-12 | Cephalon Llc | Anticorpi anti-par-2 e loro metodi d'uso |
| GB202204159D0 (en) | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| CN120835790A (zh) | 2023-01-25 | 2025-10-24 | 免疫医疗有限公司 | 偏头痛疗法 |
| WO2025172573A1 (fr) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinaisons d'inhibiteurs de par2 et d'inhibiteurs de points de contrôle immunitaires pour le traitement du cancer |
| WO2025191185A1 (fr) | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Composés à base d'azine utilisés en tant qu'inhibiteurs de par-2 et leurs utilisations thérapeutiques |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| WO2004080373A2 (fr) * | 2003-03-11 | 2004-09-23 | Bayer Healthcare Ag | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 2 active par la proteinase (par2) couple aux proteines g |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JP2008519039A (ja) * | 2004-11-04 | 2008-06-05 | ニュー イングランド メデカル センター ホスピタルズ インク | Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法 |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| AR070911A1 (es) * | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| US9315577B2 (en) | 2008-05-01 | 2016-04-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| EP2313110A1 (fr) | 2008-08-05 | 2011-04-27 | Boehringer Ingelheim International GmbH | Effecteurs de l'activation par-2 et leur utilisation dans la modulation d'une inflammation |
| EP2313364B1 (fr) * | 2008-08-07 | 2020-09-02 | Idexx Laboratories, Inc. | Procédés de détection de diméthylarginine symétrique |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| JP5932670B2 (ja) * | 2010-03-11 | 2016-06-08 | ライナット ニューロサイエンス コーポレイション | ｐＨ依存性の抗原結合を有する抗体 |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| US9540449B2 (en) * | 2012-08-13 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
| CA2953714C (fr) | 2014-06-30 | 2021-05-18 | Ralf Guenther | Anticorps anti-tnfa a liaison antigenique sensible au ph |
| MX2019010802A (es) * | 2017-03-16 | 2019-10-30 | Medimmune Ltd | Anticuerpos anti-par2 y usos de los mismos. |
-
2018
- 2018-03-16 MX MX2019010802A patent/MX2019010802A/es unknown
- 2018-03-16 CN CN201880018128.7A patent/CN110446720B/zh active Active
- 2018-03-16 JP JP2019549512A patent/JP7222901B2/ja active Active
- 2018-03-16 SG SG11201908056QA patent/SG11201908056QA/en unknown
- 2018-03-16 PT PT187141858T patent/PT3596125T/pt unknown
- 2018-03-16 DK DK18714185.8T patent/DK3596125T3/da active
- 2018-03-16 IL IL269134A patent/IL269134B2/en unknown
- 2018-03-16 UA UAA201910275A patent/UA125757C2/uk unknown
- 2018-03-16 BR BR112019018752-9A patent/BR112019018752A2/pt unknown
- 2018-03-16 EP EP18714185.8A patent/EP3596125B1/fr active Active
- 2018-03-16 EP EP25204633.9A patent/EP4681726A3/fr active Pending
- 2018-03-16 CR CR20190417A patent/CR20190417A/es unknown
- 2018-03-16 US US15/923,374 patent/US10836822B2/en active Active
- 2018-03-16 MA MA049886A patent/MA49886A/fr unknown
- 2018-03-16 AU AU2018235031A patent/AU2018235031B2/en active Active
- 2018-03-16 KR KR1020197030092A patent/KR102711884B1/ko active Active
- 2018-03-16 LT LTEPPCT/EP2018/056776T patent/LT3596125T/lt unknown
- 2018-03-16 NZ NZ757915A patent/NZ757915A/en unknown
- 2018-03-16 TW TW107109179A patent/TWI788332B/zh active
- 2018-03-16 PL PL18714185.8T patent/PL3596125T3/pl unknown
- 2018-03-16 HR HRP20251643TT patent/HRP20251643T1/hr unknown
- 2018-03-16 ES ES18714185T patent/ES3056721T3/es active Active
- 2018-03-16 SI SI201831278T patent/SI3596125T1/sl unknown
- 2018-03-16 CA CA3055251A patent/CA3055251A1/fr active Pending
- 2018-03-16 FI FIEP18714185.8T patent/FI3596125T3/fi active
- 2018-03-16 WO PCT/EP2018/056776 patent/WO2018167322A1/fr not_active Ceased
- 2018-03-16 RS RS20251336A patent/RS67581B1/sr unknown
-
2019
- 2019-09-11 ZA ZA2019/06004A patent/ZA201906004B/en unknown
- 2019-09-13 CL CL2019002626A patent/CL2019002626A1/es unknown
- 2019-09-13 PH PH12019502087A patent/PH12019502087A1/en unknown
- 2019-10-03 CO CONC2019/0010975A patent/CO2019010975A2/es unknown
-
2020
- 2020-09-29 US US17/035,956 patent/US11591389B2/en active Active
-
2021
- 2021-10-27 AU AU2021257983A patent/AU2021257983B2/en active Active
-
2023
- 2023-02-03 JP JP2023015469A patent/JP2023055895A/ja active Pending
- 2023-02-07 US US18/165,614 patent/US20230242639A1/en not_active Abandoned
-
2025
- 2025-03-18 JP JP2025043151A patent/JP2025102812A/ja active Pending
- 2025-05-27 AU AU2025203947A patent/AU2025203947A1/en active Pending
- 2025-09-19 US US19/334,502 patent/US20260078180A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3625263A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
| EP3891183A4 (fr) | Anticorps anti-claudine et leurs utilisations | |
| EP3759143A4 (fr) | Anticorps anti-tigit et leurs utilisations | |
| EP3383916A4 (fr) | Anticorps anti-cd73 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| EP3389702A4 (fr) | Anticorps anti-lag-3 et leurs utilisations | |
| MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| EP3661965A4 (fr) | Anticorps anti-cd47 et leurs utilisations | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| EP3426288A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3645563A4 (fr) | Anticorps anti-fam19a5 et leurs utilisations | |
| EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3733702A4 (fr) | Anticorps anti-lag-3 et utilisations associées | |
| EP3790586A4 (fr) | Anticorps anti-dll3 et leurs utilisations | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| EP3672987A4 (fr) | Anticorps anti-apéline et leurs utilisations | |
| EP3661555A4 (fr) | Anticorps bispécifiques et leurs utilisations |